In turn, a second-generation compound 9 was obtained and the potential for this type of compounds in therapy of autoimmune diseases such as AGS or SLE was validated in the AGS model TREX1-/- mice (Figure 10) (140). This evidence concerns the gene TREX1 and systemic lupus erythematosus.